Rare and orphan disease research represents the fastest growing area of drug development, but these studies face significant challenges, including endpoint selection and measurement.
This highly heterogeneous collection of disease is characterized by a wide range of severity, clinical presentation and rate of progression, making the selection of appropriate outcomes measures difficult and their correct administration throughout the trial paramount.
Cogstate has deep experience in cognitive and behavioral endpoint selection and management for neurodevelopmental and rare diseases.
Please fill out the form below to download the fact sheet and learn more about we support rare disease clinical trials globally.
